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Summary
 
Thioredoxin (Trx) is a ubiquitous intracellular protein disulfide oxidoreductase with a CXXC
active site that can be released by various cell types upon activation. We show here that Trx is
chemotactic for monocytes, polymorphonuclear leukocytes, and T lymphocytes, both in vitro
in the standard micro Boyden chamber migration assay and in vivo in the mouse air pouch
model. The potency of the chemotactic action of Trx for all leukocyte populations is in the
nanomolar range, comparable with that of known chemokines. However, Trx does not in-
crease intracellular Ca
 
2
 
1
 
 and its activity is not inhibited by pertussis toxin. Thus, the chemotac-
tic action of Trx differs from that of known chemokines in that it is G protein independent.
Mutation of the active site cysteines resulted in loss of chemotactic activity, suggesting that the
latter is mediated by the enzyme activity of Trx. Trx also accounted for part of the chemotactic
activity released by human T lymphotropic virus (HTLV)-1–infected cells, which was inhib-
ited by incubation with anti-Trx antibody. Since Trx production is induced by oxidants, it
represents a link between oxidative stress and inflammation that is of particular interest because
circulating Trx levels are elevated in inflammatory diseases and HIV infection.
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T
 
hioredoxin (Trx)
 
1
 
 is a 12-kD, ubiquitous intracellular
enzyme with a conserved CXXC active site that forms
 
a disulfide in the oxidized form or a dithiol in the reduced form
(1, 2). Trx catalyzes dithiol–disulfide oxidoreductions, and,
 
together with Trx reductase and nicotinamide adenindinucleo-
tide phosphate, is a general protein oxidoreductase and a hy-
drogen donor for ribonucleotide reductase essential for DNA
 
synthesis (3). In addition, it has intracellular antioxidant activity
 
and, when overexpressed, protects against oxidative stress (4–8).
Trx is secreted by monocytes, lymphocytes, and other nor-
mal or neoplastic cells by a leaderless pathway, a property it
shares with IL1-
 
b
 
 (9–13). Secreted Trx exhibits several cy-
tokine-like activities (8). In particular, Trx secreted by human
T lymphotropic virus (HTLV)-1–transformed T cells was
originally described as adult T cell leukemia–derived factor
and acts as an inducer of the IL-2 receptor (10, 14). Other ac-
tivities include activation of eosinophil functions, such as cy-
totoxicity and migration (15, 16), and potentiation of TNF
production (17). Clinically, increased Trx levels have been
reported in HIV disease (18) and in the synovial fluid of pa-
tients with rheumatoid arthritis (19). These data suggested to
us that Trx might have chemokine-like activities. We there-
fore tested the activity of Trx in a standard chemotaxis assay
in vitro and in the air pouch model in vivo. The results re-
ported here indicate that Trx is a chemotactic protein with a
potency comparable to other known chemokines.
 
1
 
Abbreviations used in this paper:
 
 GST, glutathione-
 
S
 
-transferase; HTLV,
human T lymphotropic virus; MCP, monocyte chemotactic protein; PT,
pertussis toxin; Trx, thioredoxin. 
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Materials and Methods
 
Materials.
 
Human recombinant Trx, its C32S/C35S mutant
[Trx(SGPS)], and human recombinant glutaredoxin were pre-
pared as previously described (20–22). Goat anti–human Trx
neutralizing antibody (23) was from Imco (Sweden). Control
antibody (goat antibody against 
 
Schistosoma japonicum
 
 glutathione
 
S
 
-transferase [GST]) was from Pharmacia. 
 
Spirulina
 
 Trx was from
Sigma Chemical Co.
 
Miscellaneous Assays.
 
Human Trx was measured in culture
supernatants by ELISA, as previously described (18).
 
Chemotaxis In Vitro.
 
Chemotactic activity for human mono-
cytes, PMNs, and T cells was evaluated using 48-well micro
Boyden chambers (Neuro Probe, Inc.), as previously described
(24, 25). The filters were stained and chemotactic activity was ex-
pressed as the average number of cells migrated in five oil immer-
sion fields counted.
 
Chemotaxis In Vivo.
 
Air pouch formation was induced by in-
jecting 4 ml of air 7 and 3 d before the experiment. Then, 1 
 
m
 
g
of Trx was injected into the air pouch in 1 ml of sterile, pyrogen-
free saline, containing 0.5% (wt/vol) carboxymethylcellulose
(USP grade; Sigma Chemical Co.) to avoid a rapid diffusion of
Trx from the site of injection. Control mice were injected with
this vehicle. To determine the proportion of different leukocyte
subsets, cells from Trx-treated (see Fig. 6, closed symbols) and con-
trol mice (see Fig. 6, open symbols) were stained with antibody
markers to identify granulocytes, monocyte/macrophages, and lym-
phocytes. Reagent preparation and staining methods were as previ-
ously described (26). Cells from six individual Trx-treated mice
(4 h) were analyzed. Six untreated control mice were pooled in
order to obtain sufficient cell numbers for analysis. Samples were
analyzed on a flow cytometer modified to simultaneously detect 10
fluorochromes (27). Propidium iodide exclusion identified live cells.
Granulocytes were identified as GR-1
 
1
 
 (RB6-8C5). Monocyte/
macrophages were identified as GR-1
 
2
 
, CD11b
 
1
 
 (M1/70), F4/80
 
1
 
.
Lymphocytes were identified as negative for the above-mentioned
markers and confirmed by forward and side scatter characteristics.
Animal studies were performed in accordance with Institutional
guidelines and approved by the Institutional Review Board.
 
Intracellular Ca
 
2
 
1
 
 Measurement.
 
Adherent monocytes or PMNs
on coverslips were loaded with FURA-2AM (Sigma Chemical
Co.), washed, and incubated at 37
 
8
 
C with the different stimuli.
Fluorescence was monitored using an epifluorescence microscope
equipped with fluorescence optics and dichroic mirror appropriate
for FURA-2 fluorescence. FURA-2 was excited at 350 and 380
nm every second and the emitted fluorescence was filtered be-
tween 510 and 530 nm and monitored using a CCD camera
(Dage MTI) and a Georgia Instrument Image Analyzer. Regions
of interest corresponding to individual cells were identified in
 
each experiment, and average fluorescence was recorded and
stored as individual data files. Fluorescence intensity was con-
verted into intracellular free Ca
 
2
 
1
 
 ([Ca
 
2
 
1
 
]
 
i
 
), as previously de-
scribed (28). Representative experiments are shown as fluores-
cence tracings of individual cells. Results from several experiments
are also summarized as number of responsive cells (when the stim-
ulus-induced increase of [Ca
 
2
 
1
 
]
 
i
 
 was twice the SD over the mean
of baseline values) or mean Ca
 
2
 
1
 
 increase of responsive cells.
 
Results
 
Chemotactic Activity of Trx In Vitro.
 
Testing human re-
combinant Trx for chemotactic activity towards PMNs,
monocytes, and T lymphocytes in a standard
 
 
 
in vitro chemo-
taxis assay
 
 
 
with micro Boyden chambers (Fig. 1), we found
that Trx is chemotactic for all three cell populations. The op-
timal concentration (0.1–2.5 nM; 1–30 ng/ml) and degree of
response are comparable with that of an optimal concentra-
tion of a reference chemokine (IL-8 for PMNs, monocyte
chemotactic protein [MCP]-1 for monocytes, and RANTES
for T cells, respectively). Trx showed the typical bell-shaped
dose–response curve reported for all chemokines.
To evaluate the possibility that the chemotactic activity
of Trx was specific and not due to a contaminant we used
different approaches. First, Trx was heat inactivated by
Figure 1. Chemotactic effect of Trx on
human PMNs, monocytes, and T cells. The
average number of cells migrated in five oil
immersion fields 6 SD using different con-
centrations of human recombinant Trx (d)
or boiled (30 min at 1008C) human recom-
binant Trx (s) are shown. The response to
a known chemokine (left panel, IL-8; cen-
ter panel, MCP-1; right panel, RANTES) is
also shown (e) as a reference.
Figure 2. Chemotactic activity of Trx is inhibited by an anti-Trx anti-
body. Trx was incubated for 15 min at 378C with 0.5 mg/ml goat anti–
human Trx or a control antibody (anti-GST). Trx was then assayed for
chemotactic activity for monocytes at the concentration of 2.5 nM, as de-
scribed above. Data are mean 6 SD of triplicate samples. 
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boiling, to rule out the possibility that the chemotactic ac-
tivity might be due to endotoxin, which is heat stable, or to
small contaminating peptides. As shown in Fig. 1, boiled
Trx was inactive towards all cell populations. Furthermore,
a neutralizing anti-Trx antibody, but not a control anti-
body, neutralized the chemotactic activity of Trx for hu-
man monocytes but not the activity of MCP-1 (Fig. 2).
To assess whether Trx was indeed chemotactic or if it
induced random cell migration, we performed checker-
board experiments using PMNs and monocytes. As shown
in Table I, no migration was observed when the same con-
centration of Trx was added to both the upper and lower
chambers, indicating that Trx had a true chemotactic, not
chemokinetic, activity.
To investigate the role of the protein disulfide oxi-
doreductase activity, we tested the chemotactic action of
Trx from 
 
Spirulina
 
 algae (which has the same cys-gly-pro-
cys [CGPC] active site and enzymatic activity as the mam-
malian Trx) of a C32S/C35C mutant where the CGPC ac-
tive site was substituted by a ser-gly-pro-ser [SGPS] sequence,
and of human recombinant glutaredoxin. As shown in Fig.
3, 
 
Spirulina
 
 Trx was chemotactic for PMNs and monocytes
at concentrations equivalent to those of human recombinant
Trx, whereas glutaredoxin or Trx(SGPS) were inactive.
 
Effect of Trx on Intracellular Calcium.
 
Fig. 4 shows the
trace of [Ca
 
2
 
1
 
]
 
i
 
 in single monocytes or single PMNs stimu-
lated with MCP-1, IL-8, or Trx. Consistent with previous ev-
idence (28, 29), IL-8 induced a rapid rise in intracellular Ca
 
2
 
1
 
in PMNs (Fig. 4, C and D) and MCP-1 induced a slower, but
nonetheless definitive, increase of Ca
 
2
 
1
 
 in monocytes (Fig. 4,
A and B). However, chemotactic concentrations of Trx did
not induce any Ca
 
2
 
1
 
 response in either cell population. In sev-
eral experiments analyzing up to 30 individual cells, we
never observed an effect of Trx on intracellular Ca
 
2
 
1
 
 in a con-
centration range of 1–100 ng/ml (0.083–8.3 nM) (Table II).
We also studied the effect of the G protein inhibitor,
pertussis toxin (PT), on Trx chemotactic activity on mono-
cytes. As shown in Fig. 5, the chemotactic activity of Trx
on monocytes was not inhibited by PT, whereas a marked
inhibition was observed on MCP-1 activity (Fig. 5).
 
Chemotactic Activity of Trx In Vivo.
 
We tested Trx in the
murine air pouch model of inflammation (30). 4 h after in-
jection of 1 
 
m
 
g Trx into a pouch (formed by prior subcuta-
 
Table I.
 
Checkerboard Analysis of the Effect of Trx on Monocyte and PMN Migration
 
Monocytes PMNs
Below
Above Above
0 ng/ml 3 ng/ml 30 ng/ml Below 0 ng/ml 3 ng/ml 30 ng/ml
0 ng/ml 39 
 
6
 
 4 ND ND 0 ng/ml 15 
 
6
 
 4N D N D
3 ng/ml 96 
 
6
 
 5 37 
 
6
 
 4 50 
 
6
 
 4 3 ng/ml 70 
 
6
 
 4 34 
 
6
 
 4 25 
 
6
 
 4
30 ng/ml 202 
 
6
 
 9 203 
 
6
 
 6 35 
 
6
 
 2 30 ng/ml 168 
 
6
 
 9 127 
 
6
 
 6 27 
 
6
 
 4
Different concentrations of Trx were added to the upper and/or the lower compartments of the chemotactic chambers. Results are number of mi-
grated PMNs in five immersion fields and are the mean 
 
6
 
 SD of three replicates. ND, not done.
Figure 3. Chemotactic activity of Spirulina TRX, Trx(SGPS) mutant,
or glutaredoxin on human PMNs and monocytes. The proteins were
tested at the indicated concentrations, as described in the legend to Fig. 1.
The data show the number of cells migrated in five oil immersion fields
using different concentrations of the test protein. Data are mean 6 SD of
triplicate samples.
Figure 4. Trx does not increase cytosolic Ca21 in human monocytes or
PMNs. Traces represent levels of [Ca21]i in single adherent monocytes (A
and B) or PMNs (C and D) in response to 30 ng/ml (2.5 nM) Trx (A and
C), 25 ng/ml (3 nM) IL-8 (D), or 50 ng/ml (6 nM) MCP-1 (B). Traces
are representative of 12–32 cell recordings (7 donors, 3–5 cells per cover-
slip). Arrows indicate the addition of agents to the bathing medium,
which causes a spike in the trace due to exposure to light. 
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neous injection of air, as described in Materials and Meth-
ods), the pouch was washed with medium, and infiltrated
cells were counted, stained, and analyzed by flow cytometry.
As shown in Fig. 6, injection of Trx induced a marked
infiltration of granulocytes, and, to a lesser extent, mono-
cytes and lymphocytes. Although the absolute response to
Trx varied somewhat in different experiments, granulo-
cytes were consistently the most frequent cells in the infil-
trate. Infiltration was higher at 4 h than at 24 h (data not
shown), consistent with the hypothesis that Trx acts di-
rectly as a chemotactic agent and does not cause cell infil-
tration by inducing other chemokines.
 
Trx Accounts for the Chemotactic Activity Released by
HTLV-1–transformed Cells.
 
To investigate whether Trx
could contribute to the chemotactic activity released by the
HTLV-1–transformed MT4 cell line, we studied the effect
of an anti-Trx antibody on the chemotactic activity of the
MT4 supernatants. As shown in Fig. 7, 50% of the chemo-
tactic activity of the MT4 supernatant was inhibited by an
anti–human Trx antibody. The Trx content of the MT4
supernatant, as measured by ELISA, was 6 ng/ml, which is
consistent with the potency of Trx as a chemotactic factor.
 
Discussion
 
Our data show that Trx is a potent chemoattractant for
PMNs, monocytes, and T cells. Several lines of evidence
suggest that this activity is specific and not due to a con-
taminant. In particular, chemotactic activity was observed
with different Trx preparations, including Trx from algae,
it was inactivated by boiling and by an anti-Trx antibody.
Our findings also show that Trx contributes significantly
to the chemotactic activity released in HTLV-1–infected
cells, that have long been known to secrete Trx (31). In
particular, the HTLV-1–transformed MT4 cell line sponta-
neously releases chemotactic activity for monocytes that is
not mediated by TNF, IL-8, or MCP-1 (32). We recently
purified a major monocyte chemotactic factor from MT4-
Figure 5. Chemotactic activity of Trx on monocytes is not inhibited
by PT. Monocytes were incubated with 1 mg/ml PT for 90 min at 378C,
then washed to remove PT and used for chemotaxis experiments with
Trx (30 ng/ml) or MCP-1 (25 ng/ml), as described above. Data from
two independent experiments are shown. Data are mean 6 SD of tripli-
cate samples. *P , 0.05 versus control by Student’s t test.
Table II. Trx Does Not Induce Increase of Ca21 in Single 
Monocytes and PMNs
Responsive cells Mean Ca21 increase
Monocytes %
Trx 0.83–8.3 nM 0 0
MCP-1 3 nM 82 227 6 81
FMLP 100 nM 100 310 6 41
PMNs
Trx 0.83–8.3 nM 0 0
IL-8 3 nM 67 218 6 64
FMLP 100 nM 100 260 6 103
Data are cumulative of 15–30 cells analyzed. Cells were considered re-
sponsive when the stimulus-induced increase of [Ca21]i was twice the
SD over the mean of baseline values. Mean Ca21 increase is the mean
6 SD of values of responsive cells. Data are expressed as percentage
above basal [Ca21]i.
Figure 6. Trx-induced leukocyte recruitment in the air pouch in mice.
1 mg of Trx was injected in the air pouch as described in Materials and
Methods. Control mice were injected with vehicle only. 4 h later, the
cells in the air pouch were recovered, counted, and analyzed by FACS®.
s, mean of seven control mice; d, Trx-treated mice (n 5 7).
Figure 7. Trx is a component of the chemotactic activity for PMNs re-
leased by the HTLV-1–transformed cell line MT4. Supernatants from
MT4 cells or control media were treated for 15 min at 378C with goat
anti–human Trx (0.5 mg/ml) or a control antibody (anti-GST). Superna-
tants were then assayed for chemotactic activity on PMNs as described
above. **P , 0.05 versus control by Student’s t test.1787 Bertini et al.
conditioned medium that we identified as MIP-1a/LD78
(33) and showed to be active on monocytes but only
weakly chemotactic for PMNs (33). We show here that an
anti-Trx antibody significantly inhibits the chemotactic ac-
tivity of MT4 supernatants, an observation that might ex-
plain why the known chemokines produced by these cells
could not account for all of their chemotactic activity.
As far as the mechanism of the effect of Trx is concerned,
we obtained convincing evidences that Trx does not act
through a chemokine receptor. First of all, Trx does not in-
duce an increase of intracellular Ca21, which is observed with
all chemokines, whose receptors are coupled to G proteins.
Furthermore, chemotactic activity of Trx is not inhibited by
PTX. Although chemotactic receptors have been shown to be
able to couple with both PTX-sensitive and PTX-insensitive
GTP binding proteins (34, 35), only bg subunits associated
with Gai are responsible for chemotactic receptor-mediated
cell migration (36). The finding that Trx chemotactic response
is PTX insensitive, along with the lack of effect of Trx on
intracellular Ca21, strongly argue against its direct interaction
with a seven-transmembrane domain chemotactic receptor.
In contrast, Trx may initiate signal transduction for
chemotaxis by oxidizing and cross-linking appropriate cell
surface molecules. Trx is mainly known as a protein disul-
fide–reducing enzyme; however, it can also act as protein
disulfide isomerase in the formation of disulfides during pro-
tein folding (1), particularly when in an oxidative environ-
ment (37). Thus it is possible that, in an extracellular environ-
ment, Trx acts by oxidizing thiols of one or more membrane
proteins or catalyzing isomerization reactions. However, since
Trx’s chemotactic activity is G protein independent, this puta-
tive oxidized receptor is likely to differ from any of the known
chemokine receptors. In fact, the Trx target could behave like
a “sensor”, in a fashion similar to the hemoprotein, which acts
as the oxygen sensor in the induction of erythropoietin (38).
Several lines of evidence suggest that the chemotactic ac-
tivity of Trx is due to its enzymatic action on cell surface
protein substrates. First of all, a C32S/C35S mutant of Trx
where the cysteines of CXXC active site have been mu-
tated, and that has lost enzyme activity (22), was not chemo-
tactic. Furthermore, glutaredoxin, which differs from Trx in
substrate specificity, has no chemotactic activity. In fact, al-
though Trx catalyzes the oxidation/reduction of a wide
range of inter- or intra-protein disulfides, the preferred
substrates of glutaredoxin are mixed disulfides between
proteins and glutathione, and the substrate specificity for
disulfides is very different (1, 2, 21). A further support to
this hypothesis is the chemotactic activity of Trx from Spir-
ulina. Since algal Trx has only little (z20%) similarity with
human Trx (39), but has the same conserved CGPC active
site human Trx, we think it is more likely that Trx may act
through its enzymatic activity rather than by binding to a
membrane receptor. Consistent with this, various investi-
gators have been unable to identify specific binding sites for
Trx on the cell membrane of various cell types (40–43).
Our findings suggest two different hypotheses concern-
ing the pathogenic role of Trx in infection and inflamma-
tion. First, the local release of Trx is likely to be important,
in concert with other chemokines, in recruiting cells during
infection and inflammation. Consistent with this hypothesis,
Trx is secreted by IFN-g– or endotoxin-stimulated macro-
phages or activated T lymphocytes (12, 44) and has been
measured locally in arthritic patients (19). Trx is also an
acute-phase protein in that its production by the liver is in-
creased in rats injected with LPS (45). In addition, Trx may
also be a major chemoattractant in diseases associated with
oxidative stress, such as ischemia/reperfusion, since Trx
production is induced by oxidants (46) and Trx is elevated
locally in cerebral ischemia or brain injury (47, 48) and
open-heart surgery (23). Thus, according to this hypothe-
sis, Trx might function as a signal of oxidative stress that
amplifies the cellular response at a site of inflammation.
A second hypothesis on the significance of Trx in disease
stems from the observation that Trx levels were found to be
elevated (.30 ng/ml plasma) in a proportion of HIV-
infected subjects with CD4 T cell counts ,200/ml blood
(18). Nearly all of the high-Trx subjects died within 18 mo
of the Trx measurement, although none had active opportu-
nistic infections or other signs of debilitating disease at the
time of measurement. Deaths in an otherwise similar group
of HIV-infected subjects with normal Trx levels were mini-
mal during the same period (Nakamura, H., S. de Rosa, M.
Roederer, J. Yodoi, A. Holmgren, P. Ghezzi, L.A. Herzen-
berg, and L.A. Herzenberg, manuscript in preparation).
This survival difference may be directly traceable to the
chemoattractant activity of the Trx present in circulation.
Intravenous injection of IL-8 has been shown to inhibit
PMN accumulation in response to local injection of IL-8
(49). Furthermore, leukocyte migration is impaired in trans-
genic mice overexpressing human IL-8 or MCP-1 in circu-
lation (50, 51). High levels of circulating Trx may similarly
decrease the ability of leukocytes to migrate efficiently to a
site of infection, either by counteracting the gradient of lo-
cal chemoattractants or downregulating the chemokine re-
ceptors by desensitization (or both). Consistent with this,
PMNs and monocytes from AIDS patients have been shown
to be deficient in their ability to migrate (52, 53). Thus, by
potentially interfering with chemotaxis, elevated serum Trx
levels in HIV patients could contribute to augmented sus-
ceptibility to bacterial or viral infections and hence consti-
tute a serious threat to survival in the ensuing months.
The possibility that a chemoattractant acts through its
enzymatic activity, rather than through classical receptor
binding, opens the way to new strategies aimed at inhibit-
ing its action, using enzyme inhibitors rather than receptor
antagonists or antibodies.
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